Covid-19 vaccine: what if we never found it like HIV AIDS?

[Obamot]

You skip over his little pessimistic sentence which clearly justified the question:

Nor do we sell the bear skin

Can you give us a link to a vaccine tested in a randomized, double-blind study?

Serious vaccine candidate: nearly 9 participants (China)
Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy and Safety
COV-02-IB vaccine candidate
Development: Sinovac.
Trial on 8870 participants.
Method: virus inactive
Admixture / s: aluminum
First result:.
Treatment
Preliminary phases:
Phase III - efficacy validation (for mass production): to come.
Availability:
More details:
http://www.sinovac.com/?optionid=754&auto_id=907

Like what it exists.

So I asked Izentrop and he didn't have it ... so I looked ... looked ... looked ...

It's like that when you act pro ... and it proves your good faith, (unlike some "psychoblock")

[izentrop]

Good luck to the guinea pigs !!
https://www.sudinfo.be/id223504/article ... i-teste-un
"I'm burning, my forehead is sweating, my heart is racing": a volunteer who tested an anti-covid vaccine recounts her experience

There is still a little bonus to the key https://www.lesoir.be/312808/article/20 ... e-covid-19

[phil59]

Negative the test ....

I don't understand a thing ...

My doctor told me that less than 2% were positive. (tests which were carried out on suspicion in the majority).

I wonder if covid might not be an "side effect" of another "infection" ....

[Adrien (ex-nico239)]

Negative the test ....

I don't understand a thing ...

My doctor told me that less than 2% were positive. (tests which were carried out on suspicion in the majority).

I wonder if covid might not be an "side effect" of another "infection" ....

A priori negative is positive.
Do you have any loss of taste or smell?

Did you do a lung scan?
Sometimes there are lesions without visible effects on the patient: no shortness of breath, nothing in particular and yet.

[izentrop]

A priori negative is positive.

You fill up a corner as the other says
Well already there are several kinds of test and a new one in pharmacy

the COVID-PRESTO Rapid Serological Test. This test was evaluated and validated on capillary blood obtained by pricking the fingertip by Doctor Thierry Prazuck, Head of the Infectious Diseases Department at the Orléans CHRU: "These tests have shown that 100% of patients presenting with symptoms suggestive of COVID-19 and tested positive by molecular PCR test, were immunized from 16 days after the onset of symptoms. The results fell quickly, since it only takes 10 minutes per patient to demonstrate immunization, "he explains in a company press release dated May 25. The COVID-PRESTO® test differentiates two kinds of antibodies which are, at the beginning of the disease, the Immunoglobulins M then at the stage of cure, the Immunoglobulins G. The test thus makes it possible to distinguish patients who are immunized and therefore, a priori, immune to a new infection. The Ministry of Health's website also lists the 54 RT-PCR tests validated by the CNR in France. https://sante.journaldesfemmes.fr/fiche ... resultats/

[phil59]

serologie.JPG (66.04 KiB) Viewed 1773 times

At that time, in November 2019, I had lost my taste, not very long, 2-4 weeks ....

[izentrop]

Don't worry, it's normal according to recent studies. (way of talking )

"There is currently no evidence that people who have recovered from Covid-19 and who have antibodies are immune to a second infection," said the World Health Organization (WHO) in April 2020.

A British study published in July 2020 in the scientific pre-publication journal MedRxiv also looked into the question. She suggests that the antibodies provide potential immunity to patients, but that it decreases or even disappears after a few months.

To find out, researchers from King's College London (United Kingdom) looked at the immune response of 90 patients and healthcare professionals from the Guy's and St Thomas' NHS Foundation Trust who were affected by Covid-19. While 60% of the volunteers had developed strong antibodies in response to the infection, the researchers found that only 17% of the patients had retained that same level of antibodies three months later.

These results therefore suggest that the antibodies would have a limited lifespan and that patients already affected by Covid-19 could therefore be re-infected. An observation that once again calls into question the idea of ​​a potential collective immunity. https://www.femmeactuelle.fr/sante/news ... on-2095908

[Adrien (ex-nico239)]

At that time, in November 2019, I had lost my taste, not very long, 2-4 weeks ....

Ah ok it's a serology ...

Indeed 2 to 4 weeks is rather long and it really corresponds to a reliable symptom.

No other symptoms at this time?

[Obamot]

At that time, in November 2019, I had lost my taste, not very long, 2-4 weeks ....

Yes, but after 3 months the igGs (biological markers) can disappear. The result of the test at such a distant time, seems to me more there to reassure you (that you would not be infected with risk of symptoms) than anything else, although in some people, igGs persist even after months (probably and especially if the person has had strong enough symptoms, which does not seem to be the case AND which does not mean that your body would no longer recognize the virus if you were still in contact with it one day: since anyway, when covid-19 will have been around the planet in 5 years, in principle we will ALL have been in contact with it at least once ...).
But for a second exposure, there would be no need to worry according to Professor Pittet of the HUG:
"- if we have already had covid-19, it could be (very hypothetically) that we fall ill again another time, (if we are in contact with the virus again) but we would never be as sick as the first time...

And we must add that we do not know if this virus would be seasonal (or not), and that “the second time” would depend greatly on whether our immune response would have remained the same in the meantime, would have improved or deteriorated (because we would have disciplined ourselves or relaxed ...)

Don't worry, it's normal according to recent studies. (way of talking )

Should already see if your ”way of talking"Agrees with your"way of thinking", because until then (just like your Ayatollah comrades) you made US understand “that you had to go to bed in front of any study, as long as it spoke badly of the HCQ + AZ treatment"[...] whereas any scientist would take into account ALL the studies!
(and not exclusively those who are against)

[Christophe]

Capitalism, true to itself ...

Vaccine against Covid-19: markets ignite on biotechs

The coronavirus pandemic has inoculated the Stock Exchange virus into many individuals. With the hope of betting on the first cure for Covid-19, investments in young innovative biotechnology companies have recorded strong growth in recent months. But beware of the scrapping, the biotechnology market is one of the riskiest.

Biotech companies have experienced a real boom in the financial markets in recent months. The Covid-19 pandemic is prompting many investors to bet big on young companies likely to find a cure for the virus. Thus, American biotechs have raised more than $ 9 billion on the stock market in recent months, against "only" $ 6,5 billion in the whole of 2018, according to data from Dealogic. This blind race for a drug or a miracle vaccine risks leaving investors behind.

"This phenomenon comes mainly from individual investors, remarks Lydia Haueter, manager of the biotech fund at Pictet AM. But biotech is one of the most volatile markets." These companies often only have one or two candidate products in stock for treatment, and often none on the market. They must therefore finance their research and development, without yet having significant income. “Even as a specialist, you need a very fine diversification and risk assessment approach,” continues Lydia Haueter. “This requires a certain expertise.”

Wave of IPOs

But the promises of its biotechs are too good not to attract investors, eager to generate a quick profit. Young companies benefit from this. The number of IPOs of young biotechs has increased, each of the newcomers having seen its price increase. This is the case of the German CureVac, introduced on Wall Street on August 14 and whose market capitalization is around 10 billion dollars. Made famous by a rumor of a buyout orchestrated by Donald Trump, his Covid-19 vaccine project is only in phase 1 of the clinical tests necessary to validate it. Its course remains strewn with possible pitfalls before a possible marketing of a product, which would take months.

In all, the World Health Organization (WHO) has identified 168 candidates for the vaccine against Covid-19 worldwide. Moderna's innovative technology is one of them, but it has never been seen in action before. The American biotech has however seen the price of its share go from nearly 19 dollars in January, to nearly 70 dollars at the end of August, for a valuation of more than 26 billion dollars.

States are also joining the fight. The US government has already signed a $ 1,3 billion contract with US biotech Moderna for the purchase of one million doses. Its candidate for the vaccine is among the most advanced in the world, it is in phase 3 of clinical trials, just like that of the alliances between the University of Oxford and AstraZeneca, or that of Pfizer and BioNTech. "The contributions of money by the States do not constitute a reduction of the risks, however warns Lydia Haueter.

The stock market which is causing the prices of young biotechs to soar, raises the risk of the bursting of a small financial bubble. Biotechs that fail before they are put on the market - that is to say, the vast majority of them - will see their value drastically reduced. Such a risk for a professional financial actor remains, in general, under control because it is diluted with other values. But for individuals betting their savings, this risk can be devastating ...

https://www.novethic.fr/actualite/finan ... 48937.html